Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the incidence of hemorrhagic events in
patients treated for non-valvular atrial fibrillation with DU-176b at each dose level versus
warfarin potassium (warfarin). The secondary objective includes between-group comparisons
with regard to incidence of thromboembolic events, pharmacodynamic parameters, and biomarkers
for the efficacy evaluation, as well as incidence of adverse events and adverse reaction for
the safety evaluation.